Varex Imaging (VREX): OEM-centric components, recurring services, and concentrated customer exposure

Varex Imaging designs and manufactures X‑ray imaging components and monetizes through three primary channels: hardware sales of critical OEM components (X‑ray tubes, detectors, generators), software licensing for image processing, and long‑term service and replacement parts agreements. The company’s business is highly OEM‑driven, global in reach, and meaningfully concentrated: top five customers accounted for approximately 40% of revenue in FY2025, creating both pricing leverage and single‑counterparty concentration risk for investors. For an investor or operator evaluating VREX customer exposure, the core thesis is straightforward: Varex is a specialized, mission‑critical supplier to a small set of large medical OEMs where contractual structures and product criticality drive margins and cyclical revenue patterns. Learn more about how we track customer relationships at NullExposure: https://nullexposure.com/

How Varex wins business and how the model monetizes

Varex sells engineered components that are embedded inside medical imaging systems built by large OEMs. The company’s revenue mix combines one‑time hardware sales, recurring replacement parts and service work, and software licensing fees. Varex’s go‑to‑market includes direct OEM supply, third‑party distributors and independent service companies, and some direct end‑user replacement sales — a diversified set of channels that nonetheless centers on major equipment manufacturers.

Key operating characteristics that shape valuation and risk:

• Contracting posture and maturity: Varex maintains multi‑year pricing agreements with established customers and retains long‑term service contracts (for example, Linatron service agreements), which provide revenue visibility and backlog conversion over time. Company filings report an estimated backlog of roughly $262 million as of October 3, 2025.
• Counterparty profile and concentration: Customers are primarily large enterprise OEMs, with the top five customers representing roughly 40% of fiscal 2025 revenue — a material concentration that increases earnings volatility but also reflects deep OEM integration.
• Product criticality and margins: Varex supplies components that are mission‑critical within imaging systems, giving it pricing leverage but also operational dependency on OEM product cycles and capital equipment spending.
• Global footprint and FX exposure: Sales span the Americas, EMEA, APAC and Latin America, exposing the company to geographic demand cycles and currency translation effects.

These operating signals indicate a capital‑goods vendor with recurring aftermarket economics and concentrated counterparty risk, a profile that supports premium relationships with OEM customers but requires active monitoring of order backlogs and OEM product cycles.

Customer relationships investors should track

Below I cover every customer relationship disclosed in the available results and the primary source supporting each mention.

Canon Medical Systems

Varex lists Canon Medical Systems among its top five customers, with top‑five customers collectively accounting for about 40% of total revenue in fiscal year 2025. This underscores Canon’s role as a material OEM customer driving a substantial share of Varex sales. Source: TradingView summary of Varex FY2025 10‑K (reported March 2026).

Siemens Healthineers

Siemens Healthineers is similarly named in Varex’s FY2025 top‑five customer disclosure, indicating that Varex supplies Siemens with critical X‑ray imaging components and contributes materially to overall revenue concentration. Source: TradingView summary of Varex FY2025 10‑K (reported March 2026).

Toshiba Medical

Varex agreed to supply Toshiba Medical with computed tomography tubes as part of a prior transaction tied to Varex’s medical imaging acquisitions; press coverage from the acquisition period describes Varex supplying CT tubes for integration into Toshiba CT systems. This relationship reflects historical commercial supply of major CT components to a large OEM. Source: MassDevice report on Varex’s PerkinElmer Medical Imaging acquisition (FY2017 coverage).

What the relationship mix implies for operational risk and upside

Varex’s customer base and contract structure create a clear set of tradeoffs for investors:

• Concentration risk is material. With the top five customers contributing about 40% of FY2025 revenue, loss of or adverse pricing with any single OEM would have an outsized earnings impact. This is a core valuation risk that must be monitored alongside OEM product cycles and capital expenditures.
• Long‑term contracts and service agreements provide revenue visibility. Multi‑year pricing agreements and long‑term service contracts (explicitly referenced for Linatron products) smooth revenue recognition and sustain aftermarket margins, supporting predictable cash flow conversion when backlog converts to revenue.
• Product criticality strengthens negotiating posture but increases exposure to OEM design decisions. Because Varex components are embedded and integral to imaging system functionality, the company benefits from customer stickiness, but it is also exposed to OEM decisions on supplier selection and vertical integration.
• Global sales diversify demand but add FX and regional cycle risk. Sales across Americas, EMEA, APAC and LATAM reduce single‑market exposure but make reported results sensitive to currency swings and regional healthcare CAPEX trends.

Backlog and active engagements: Varex reported an estimated backlog of about $262 million at the start of fiscal 2026, indicating an active funnel of orders that will convert over the coming quarters and serving as a near‑term revenue buffer.

(If you want a deeper breakdown of counterparty concentration and contract terms to model downside scenarios, review our collection of customer relationship intelligence at https://nullexposure.com/.)

Investment implications and risk checklist

For portfolio managers and operators, the investment case is a balance of structural niche strength and concentration risk:

• Upside drivers: critical OEM positioning, recurring aftermarket service revenue, and software licensing that can expand margin profile.
• Key risks: significant customer concentration, cyclical demand tied to capital equipment purchases, and negative recent EPS despite positive operating margin metrics in some periods; Varex reported TTM revenue of $854.4 million and a negative diluted EPS historically.
• Valuation context: The company’s marketplace metrics show mixed signals — modest Price‑to‑Sales and near‑book valuations alongside leverage to earnings recovery — making execution on aftermarket growth and margin expansion the primary value catalyst.

If your diligence process prioritizes counterparty stability and contract tenure, Varex’s long‑dated pricing agreements and service contracts are positive signals — but they must be weighed against the high concentration of revenue among a handful of OEMs.

Explore a consolidated view of Varex customer exposure and similar OEM relationships at NullExposure: https://nullexposure.com/

Bottom line: watch OEM concentration, backlog conversion, and service growth

Varex is a specialist supplier whose monetization model blends one‑off hardware revenues with recurring software licenses and long‑term service contracts. That hybrid model supports higher‑quality earnings when backlog converts and aftermarket sales scale, but top‑customer concentration (40% from the top five in FY2025) and sensitivity to OEM equipment cycles are the principal risks investors must underwrite. For investors and operators focused on supplier economics in medical imaging, the key monitoring items are order backlog trends, OEM capital spending, and expansion of software and service revenue streams.

To examine Varex’s customer relationships alongside peers and to download relationship evidence, visit NullExposure for full coverage: https://nullexposure.com/